Targeting VDAC and Autophagy in Head and Neck Oral Squamous Carcinoma: Synergy of Itraconazole and Hydroxychloroquine
Oral Diseases · 2026-09 · 32 (9) · 2695-2712
DOI: 10.1111/odi.70374 ↗Kurz gefasst
Fachartikel in der Zeitschrift Oral Diseases, online erschienen am 10.06.2026. Verfasst von Javiera Carrasco-Rojas und 9 weiteren Autor:innen. Beteiligte Einrichtung: Institute for Research in Dental Sciences (ICOD), Faculty of Dentistry, Universidad de Chile, Santiago, Chile. Hauptthemen laut MEDLINE: Hydroxychloroquine, Itraconazole, Autophagy, Mouth Neoplasms. Die Arbeit nennt 59 Literaturangaben. Gefördert von: Fondo Nacional de Desarrollo Científico y Tecnológico.
Abstract (Originalsprache)
Objective
Oral squamous cell carcinoma (OSCC), a common subtype of head and neck cancer (HNSC), impairs essential functions such as breathing, swallowing, and speech. This study aimed to evaluate the therapeutic potential of targeting mitochondrial pathways via inhibition of Voltage‐Dependent Anionic Channel 1 (VDAC1) using itraconazole (ITRA) and to assess the synergistic effect of combining VDAC1 inhibition with autophagy inhibition using hydroxychloroquine (HCQ).
Methods
The effects of ITRA, HCQ, and their combinations with cisplatin were tested in various HNSC models, including monolayer cultures, hypoxic conditions, 3D spheroids, and an in vivo xenograft model. The study also examined the role of the VDAC1‐Hexokinase‐II complex and the impact of autophagy under metabolic stress.
Results
ITRA alone showed limited cytotoxicity, but its combination with HCQ significantly enhanced antitumoral activity. Synergistic effects were observed with HCQ + ITRA, HCQ + cisplatin, and ITRA + cisplatin in all in vitro models. In vivo, HCQ alone and in combination with ITRA reduced tumor growth without adverse effects.
Conclusions
Taken together, these findings support itraconazole as a promising candidate for further in vivo and clinical investigation in selected oral cancers, including HNSCC and OSCC. Nevertheless, the definition of clinical treatment schedules will require additional comprehensive pharmacokinetic, toxicological, and clinical studies.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Institute for Research in Dental Sciences (ICOD), Faculty of Dentistry, Universidad de Chile, Santiago, Chile.
- Institute for Research in Biomedical Sciences, Medicine Faculty, Universidad de Chile, Santiago, Chile.
- Instituto de Farmacología y morfofisiología, Facultad de Ciencias Veterinarias, Universidad Austral de Chile, Valdivia, Chile.
ORCID-Profile: Sebastián Yévenes
Förderung
- Fondo Nacional de Desarrollo Científico y Tecnológico
Zitieren
APA
Carrasco-Rojas, J., Olmedo, I., Martínez, D., Yévenes, S., López-Muñoz, R., Faúndez, J., Catalán, M., Gutiérrez, K., Molina-Berríos, A., & Jara, J. A. (2026). Targeting VDAC and Autophagy in Head and Neck Oral Squamous Carcinoma: Synergy of Itraconazole and Hydroxychloroquine. Oral Diseases, 32(9), 2695-2712. https://doi.org/10.1111/odi.70374
Vancouver
Carrasco-Rojas J, Olmedo I, Martínez D, Yévenes S, López-Muñoz R, Faúndez J, et al. Targeting VDAC and Autophagy in Head and Neck Oral Squamous Carcinoma: Synergy of Itraconazole and Hydroxychloroquine. Oral Diseases. 2026;32(9):2695-2712. doi:10.1111/odi.70374
BibTeX
@article{CarrascoRojas2026,
author = {Carrasco-Rojas, Javiera and Olmedo, Ivonne and Martínez, Daniela and Yévenes, Sebastián and López-Muñoz, Rodrigo and Faúndez, Jennifer and Catalán, Mabel and Gutiérrez, Karla and Molina-Berríos, Alfredo and Jara, José A},
title = {Targeting VDAC and Autophagy in Head and Neck Oral Squamous Carcinoma: Synergy of Itraconazole and Hydroxychloroquine},
journal = {Oral Diseases},
year = {2026},
volume = {32},
number = {9},
pages = {2695--2712},
doi = {10.1111/odi.70374}
}
EUVIMED